---
document_datetime: 2025-12-02 06:20:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-krka.html
document_name: abiraterone-krka.html
version: success
processing_time: 0.1284264
conversion_datetime: 2025-12-24 01:16:04.329356
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Abiraterone Krka

[RSS](/en/individual-human-medicine.xml/67452)

##### Authorised

This medicine is authorised for use in the European Union

abiraterone acetate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Abiraterone Krka](#more-information-on-abiraterone-krka-1615)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Abiraterone Krka is a cancer medicine used to treat men with metastatic prostate cancer. This is cancer that affects the prostate gland (a gland of the male reproductive system). It is used when the cancer has spread to other parts of the body (metastatic).

Abiraterone Krka is used together with prednisone or prednisolone (anti-inflammatory medicines):

- when the cancer is newly diagnosed, high risk and sensitive to hormones; Abiraterone Krka is then used in combination with a treatment called androgen deprivation therapy;
- when medical castration (using medicines to stop the production of male hormones) with androgen deprivation therapy has not worked or no longer works in men who have either no symptoms or only mild symptoms of the disease, and who do not yet need chemotherapy (cancer medicines);
- when medical or surgical castration and chemotherapy containing docetaxel have not worked or no longer work.

Abiraterone Krka contains the active substance abiraterone acetate and is a 'generic medicine'. This means that Abiraterone Krka contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Zytiga.

Expand section

Collapse section

## How is Abiraterone Krka used?

Abiraterone Krka is available as tablets and can only be obtained with a prescription. The recommended dose is 1,000 mg taken once a day on an empty stomach. This means that the patient should wait at least 2 hours after eating before taking the medicine and must not eat for at least 1 hour after taking the medicine. If patients develop liver problems, treatment should be stopped. Treatment may be resumed at a reduced dose if liver function returns to normal.

For more information about using Abiraterone Krka, see the package leaflet or contact your doctor or pharmacist.

## How does Abiraterone Krka work?

The active substance in Abiraterone Krka, abiraterone acetate, is changed in the body to abiraterone which stops the body producing testosterone, a male hormone. Abiraterone does this by blocking an enzyme called CYP17 found in the testes and elsewhere in the body. Because the cancer needs a supply of testosterone to survive and grow, by reducing the production of testosterone, Abiraterone Krka may slow the growth of the prostate cancer.

## How has Abiraterone Krka been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Zytiga, and do not need to be repeated for Abiraterone Krka.

As for every medicine, the company provided studies on the quality of Abiraterone Krka. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Abiraterone Krka?

Because Abiraterone Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Abiraterone Krka authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Abiraterone Krka has been shown to have comparable quality and to be bioequivalent to Zytiga. Therefore, the Agency's view was that, as for Zytiga, the benefits of Abiraterone Krka outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Abiraterone Krka?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abiraterone Krka have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Abiraterone Krka are continuously monitored. Side effects reported with Abiraterone Krka are carefully evaluated and any necessary action taken to protect patients.

## Other information about Abiraterone Krka

Abiraterone Krka received a marketing authorisation valid throughout the EU on 24 June 2021.

Abiraterone Krka : EPAR - Medicine overview

Reference Number: EMA/258413/2021

English (EN) (165.29 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/overview/abiraterone-krka-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-550)

български (BG) (199.29 KB - PDF)

**First published:**

23/11/2021

[View](/bg/documents/overview/abiraterone-krka-epar-medicine-overview_bg.pdf)

español (ES) (177.76 KB - PDF)

**First published:**

23/11/2021

[View](/es/documents/overview/abiraterone-krka-epar-medicine-overview_es.pdf)

čeština (CS) (197.14 KB - PDF)

**First published:**

23/11/2021

[View](/cs/documents/overview/abiraterone-krka-epar-medicine-overview_cs.pdf)

dansk (DA) (175.74 KB - PDF)

**First published:**

23/11/2021

[View](/da/documents/overview/abiraterone-krka-epar-medicine-overview_da.pdf)

Deutsch (DE) (178.61 KB - PDF)

**First published:**

23/11/2021

[View](/de/documents/overview/abiraterone-krka-epar-medicine-overview_de.pdf)

eesti keel (ET) (163.5 KB - PDF)

**First published:**

23/11/2021

[View](/et/documents/overview/abiraterone-krka-epar-medicine-overview_et.pdf)

ελληνικά (EL) (201.16 KB - PDF)

**First published:**

23/11/2021

[View](/el/documents/overview/abiraterone-krka-epar-medicine-overview_el.pdf)

français (FR) (178.08 KB - PDF)

**First published:**

23/11/2021

[View](/fr/documents/overview/abiraterone-krka-epar-medicine-overview_fr.pdf)

hrvatski (HR) (193.71 KB - PDF)

**First published:**

23/11/2021

[View](/hr/documents/overview/abiraterone-krka-epar-medicine-overview_hr.pdf)

italiano (IT) (175.06 KB - PDF)

**First published:**

23/11/2021

[View](/it/documents/overview/abiraterone-krka-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (213.36 KB - PDF)

**First published:**

23/11/2021

[View](/lv/documents/overview/abiraterone-krka-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (195.69 KB - PDF)

**First published:**

23/11/2021

[View](/lt/documents/overview/abiraterone-krka-epar-medicine-overview_lt.pdf)

magyar (HU) (197.22 KB - PDF)

**First published:**

23/11/2021

[View](/hu/documents/overview/abiraterone-krka-epar-medicine-overview_hu.pdf)

Malti (MT) (198.6 KB - PDF)

**First published:**

23/11/2021

[View](/mt/documents/overview/abiraterone-krka-epar-medicine-overview_mt.pdf)

Nederlands (NL) (176.65 KB - PDF)

**First published:**

23/11/2021

[View](/nl/documents/overview/abiraterone-krka-epar-medicine-overview_nl.pdf)

polski (PL) (199.1 KB - PDF)

**First published:**

23/11/2021

[View](/pl/documents/overview/abiraterone-krka-epar-medicine-overview_pl.pdf)

português (PT) (166.53 KB - PDF)

**First published:**

23/11/2021

[View](/pt/documents/overview/abiraterone-krka-epar-medicine-overview_pt.pdf)

română (RO) (193.92 KB - PDF)

**First published:**

23/11/2021

[View](/ro/documents/overview/abiraterone-krka-epar-medicine-overview_ro.pdf)

slovenčina (SK) (187.32 KB - PDF)

**First published:**

23/11/2021

[View](/sk/documents/overview/abiraterone-krka-epar-medicine-overview_sk.pdf)

slovenščina (SL) (193.6 KB - PDF)

**First published:**

23/11/2021

[View](/sl/documents/overview/abiraterone-krka-epar-medicine-overview_sl.pdf)

Suomi (FI) (173.81 KB - PDF)

**First published:**

23/11/2021

[View](/fi/documents/overview/abiraterone-krka-epar-medicine-overview_fi.pdf)

svenska (SV) (175.08 KB - PDF)

**First published:**

23/11/2021

[View](/sv/documents/overview/abiraterone-krka-epar-medicine-overview_sv.pdf)

Abiraterone Krka : EPAR - Risk-management-plan summary

English (EN) (173.89 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/rmp-summary/abiraterone-krka-epar-risk-management-plan-summary_en.pdf)

## Product information

Abiraterone Krka : EPAR - Product information

English (EN) (763.24 KB - PDF)

**First published:** 23/11/2021

**Last updated:** 31/01/2025

[View](/en/documents/product-information/abiraterone-krka-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-670)

български (BG) (728.51 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/bg/documents/product-information/abiraterone-krka-epar-product-information_bg.pdf)

español (ES) (801.57 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/es/documents/product-information/abiraterone-krka-epar-product-information_es.pdf)

čeština (CS) (1.61 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/cs/documents/product-information/abiraterone-krka-epar-product-information_cs.pdf)

dansk (DA) (1.55 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/da/documents/product-information/abiraterone-krka-epar-product-information_da.pdf)

Deutsch (DE) (600.02 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/de/documents/product-information/abiraterone-krka-epar-product-information_de.pdf)

eesti keel (ET) (748.06 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/et/documents/product-information/abiraterone-krka-epar-product-information_et.pdf)

ελληνικά (EL) (1017.4 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/el/documents/product-information/abiraterone-krka-epar-product-information_el.pdf)

français (FR) (845.95 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/fr/documents/product-information/abiraterone-krka-epar-product-information_fr.pdf)

hrvatski (HR) (842.33 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/hr/documents/product-information/abiraterone-krka-epar-product-information_hr.pdf)

íslenska (IS) (793.67 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/is/documents/product-information/abiraterone-krka-epar-product-information_is.pdf)

italiano (IT) (917.92 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/it/documents/product-information/abiraterone-krka-epar-product-information_it.pdf)

latviešu valoda (LV) (749.64 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/lv/documents/product-information/abiraterone-krka-epar-product-information_lv.pdf)

lietuvių kalba (LT) (891.48 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/lt/documents/product-information/abiraterone-krka-epar-product-information_lt.pdf)

magyar (HU) (817.07 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/hu/documents/product-information/abiraterone-krka-epar-product-information_hu.pdf)

Malti (MT) (712.53 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/mt/documents/product-information/abiraterone-krka-epar-product-information_mt.pdf)

Nederlands (NL) (834.73 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/nl/documents/product-information/abiraterone-krka-epar-product-information_nl.pdf)

norsk (NO) (888.94 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/no/documents/product-information/abiraterone-krka-epar-product-information_no.pdf)

polski (PL) (1.08 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/pl/documents/product-information/abiraterone-krka-epar-product-information_pl.pdf)

português (PT) (1.31 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/pt/documents/product-information/abiraterone-krka-epar-product-information_pt.pdf)

română (RO) (733.96 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/ro/documents/product-information/abiraterone-krka-epar-product-information_ro.pdf)

slovenčina (SK) (1.85 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/sk/documents/product-information/abiraterone-krka-epar-product-information_sk.pdf)

slovenščina (SL) (1.41 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/sl/documents/product-information/abiraterone-krka-epar-product-information_sl.pdf)

Suomi (FI) (1 MB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/fi/documents/product-information/abiraterone-krka-epar-product-information_fi.pdf)

svenska (SV) (805.41 KB - PDF)

**First published:**

23/11/2021

**Last updated:**

31/01/2025

[View](/sv/documents/product-information/abiraterone-krka-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0007 28/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Abiraterone Krka : EPAR - All authorised presentations

English (EN) (59.53 KB - PDF)

**First published:** 23/11/2021

[View](/en/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-933)

български (BG) (69.02 KB - PDF)

**First published:**

23/11/2021

[View](/bg/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.99 KB - PDF)

**First published:**

23/11/2021

[View](/es/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.37 KB - PDF)

**First published:**

23/11/2021

[View](/cs/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.92 KB - PDF)

**First published:**

23/11/2021

[View](/da/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.13 KB - PDF)

**First published:**

23/11/2021

[View](/de/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.75 KB - PDF)

**First published:**

23/11/2021

[View](/et/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.29 KB - PDF)

**First published:**

23/11/2021

[View](/el/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_el.pdf)

français (FR) (38.93 KB - PDF)

**First published:**

23/11/2021

[View](/fr/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (80.25 KB - PDF)

**First published:**

23/11/2021

[View](/hr/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.75 KB - PDF)

**First published:**

23/11/2021

[View](/is/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.55 KB - PDF)

**First published:**

23/11/2021

[View](/it/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (77.39 KB - PDF)

**First published:**

23/11/2021

[View](/lv/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.32 KB - PDF)

**First published:**

23/11/2021

[View](/lt/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.87 KB - PDF)

**First published:**

23/11/2021

[View](/hu/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.58 KB - PDF)

**First published:**

23/11/2021

[View](/mt/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.71 KB - PDF)

**First published:**

23/11/2021

[View](/nl/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.8 KB - PDF)

**First published:**

23/11/2021

[View](/no/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.38 KB - PDF)

**First published:**

23/11/2021

[View](/pl/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.59 KB - PDF)

**First published:**

23/11/2021

[View](/pt/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_pt.pdf)

română (RO) (77.09 KB - PDF)

**First published:**

23/11/2021

[View](/ro/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.99 KB - PDF)

**First published:**

23/11/2021

[View](/sk/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.51 KB - PDF)

**First published:**

23/11/2021

[View](/sl/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.27 KB - PDF)

**First published:**

23/11/2021

[View](/fi/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59 KB - PDF)

**First published:**

23/11/2021

[View](/sv/documents/all-authorised-presentations/abiraterone-krka-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Abiraterone Krka Active substance abiraterone acetate International non-proprietary name (INN) or common name abiraterone acetate Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L02BX03

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Abiraterone Krka is indicated with prednisone or prednisolone for:

- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

## Authorisation details

EMA product number EMEA/H/C/005649

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Šmarješka cesta 6

Opinion adopted 22/04/2021 Marketing authorisation issued 24/06/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Abiraterone Krka : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (108.92 KB - PDF)

**First published:** 06/07/2022

**Last updated:** 31/01/2025

[View](/en/documents/procedural-steps-after/abiraterone-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Abiraterone Krka : EPAR - Public assessment report

Adopted

Reference Number: EMA/653711/2021

English (EN) (1.31 MB - PDF)

**First published:** 23/11/2021

[View](/en/documents/assessment-report/abiraterone-krka-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Abiraterone Krka

Adopted

Reference Number: EMA/CHMP/211070/2021

English (EN) (110.39 KB - PDF)

**First published:** 23/04/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-abiraterone-krka_en.pdf)

#### More information on Abiraterone Krka

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 31/01/2025

## Share this page

[Back to top](#main-content)